Outcomes of 6 Human Leukocyte Antigen-Mismatched Living Donor Kidney Transplant: A Study With Biopsy Amendment

Basit Öğe Kaydı
dc.authoridOkut, Gokalp/0000-0002-3641-5625
dc.contributor.authorKaratas, Murat
dc.contributor.authorOkut, Gokalp
dc.contributor.authorSimsek, Cenk
dc.contributor.authorDogan, Sait Murat
dc.contributor.authorTatar, Erhan
dc.contributor.authorUslu, Adam
dc.date.accessioned2024-08-04T20:51:51Z
dc.date.available2024-08-04T20:51:51Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description17th Virtual Congress of the Middle-East-Society-for-Organ-Transplantation (MESOT) -- SEP 03-05, 2021 -- ELECTR NETWORKen_US
dc.description.abstractObjectives: In this study, we examined the graft and patient survival outcomes in patients with end-stage kidney disease who received 6 HLA-mismatched incompatible living donor kidney transplant. Materials and Methods: Patients who underwent living donor kidney transplant between January 2010 and March 2020 were evaluated retrospectively. Group A included kidney transplant recipients with 6 HLA mismatches, and group B included kidney transplant recipients with 0 to 5 HLA mismatches. Patients with <1 year of follow-up were excluded. All rejection episodes were diagnosed via Tru-Cut biopsy and histopathological evaluation. Results: There were 15 patients in group A and 176 patients in group B. The mean follow-up was 54.1 +/- 30 months. The number of patients who underwent pretransplant immune desensitization and received tacrolimus-based triple maintenance immunosuppression therapy was significantly higher in group A. In group A, there were 13 acute rejections seen in 9 patients (81%); in group B, there were 67 acute rejections seen in 51 patients (28.9%; P =.019). No differences were observed between the groups in terms of baseline glomerular filtration rate (60 +/- 16 vs 61.6 +/- 20 mL/min/1.72 m(2); P =.76), final control glomerular filtration rate (60.7 +/- 15 vs 58 +/- 19 mL/ min/1.72 m(2); P =.59), graft loss (0% vs 4%; P =.94), and mortality (6.6% vs 3%; P =.39). Conclusions: The presence of 6 HLA mismatches was associated with higher rates of biopsy-proven acute rejection. However, 6 HLA-mismatched incompatible living donor kidney transplant can be safely performed in centers where posttransplant followup is supported by indication and protocol biopsies and where there is a pathological infrastructure with extensive knowledge and experience.en_US
dc.description.sponsorshipMiddle E Soc Organ Transplantaten_US
dc.identifier.doi10.6002/ect.MESOT2021.P73
dc.identifier.endpage152en_US
dc.identifier.issn1304-0855
dc.identifier.issn2146-8427
dc.identifier.issue3en_US
dc.identifier.pmid35384827en_US
dc.identifier.scopus2-s2.0-85127665553en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage149en_US
dc.identifier.urihttps://doi.org/10.6002/ect.MESOT2021.P73
dc.identifier.urihttps://hdl.handle.net/11616/100591
dc.identifier.volume20en_US
dc.identifier.wosWOS:000915505100030en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBaskent Univen_US
dc.relation.ispartofExperimental and Clinical Transplantationen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcute rejectionen_US
dc.subjectGraft survivalen_US
dc.subjectMortalityen_US
dc.titleOutcomes of 6 Human Leukocyte Antigen-Mismatched Living Donor Kidney Transplant: A Study With Biopsy Amendmenten_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu